

Press Release

PR Contact

InspiroGene by McKesson Lindsay Yanek, Communications <u>Lindsay.Yanek@McKesson.com</u>

InspiroGene by McKesson Partners with Vertex to Expand Distribution Options for CASGEVY® (exagamglogene autotemcel)

Partnership demonstrates commitment to advancing cell and gene therapies for patients living with debilitating diseases

IRVING, Texas, November 14, 2024 — <u>InspiroGene™ by McKesson</u>, a dedicated business focused on supporting the commercialization of cell and gene therapies (CGTs), today announced it has been selected by Vertex Pharmaceuticals Incorporated to expand commercial distribution options for CASGEVY®.

CASGEVY (exagamglogene autotemcel) is the first CRISPR-based gene-editing therapy approved by the U.S. Food and Drug Administration (FDA) and is indicated for the treatment of patients 12 years and older with sickle cell disease (SCD) with recurrent vaso-occlusive crises or transfusion-dependent β-thalassemia (TDT).

"Sickle cell disease is a rare and life-threatening blood disorder with significant unmet needs," said Joe DePinto, Head of Cell, Gene, and Advanced Therapies at McKesson. "We are proud of this partnership with Vertex that supports bringing CASGEVY to patients in need and advances medicines of the future. By leveraging our extensive supply chain expertise and customer-centric approach, our cell and gene therapy business is supporting innovative medicines advance from clinical development to commercial success."

InspiroGene will partner with Vertex to expand distribution options for CASGEVY. InspiroGene will serve a dual role – leveraging <u>Biologics By McKessonTM</u> specialty pharmacy and <u>McKesson Plasma & Biologics</u> specialty distributor.

About InspiroGene by McKesson

InspiroGene by McKesson ("InspiroGene") is a dedicated business unit focused solely on supporting the commercialization of cell and gene therapies (CGTs). At InspiroGene, we turn CGT innovation into a reality. We offer flexible, sustainable solutions to help manufacturers, payers, and providers navigate the complex CGT commercialization landscape. As an enduring ally, we're dedicated to transforming patient care and driving better health outcomes. Learn more about the InspiroGene advantage at InspiroGene.com.

About McKesson Corporation

McKesson Corporation is a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere. Our teams partner with biopharma companies, care providers, pharmacies, manufacturers, governments, and others to deliver insights, products, and services to help make quality care more accessible and affordable. Learn more about how McKesson is impacting virtually every aspect of healthcare at McKesson.com and read Qur Stories.